ARTICLE | Clinical News
PRT062070: Phase I/II started
October 21, 2013 7:00 AM UTC
Portola began an open-label Phase I/II trial of PRT2070. The Phase I portion will evaluate escalating doses of PTR2070 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small ...